Literature DB >> 11315990

Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.

L Verlinden1, A Verstuyf, M Quack, M Van Camp, E Van Etten, P De Clercq, M Vandewalle, C Carlberg, R Bouillon.   

Abstract

This study provides a detailed and exact evaluation of the interactions between vitamin D3 receptor (VDR), retinoid X receptor (RXR), and vitamin D3 responsive elements (VDREs) mediated by two novel 14-epianalogs of 1,25-dihydroxyvitamin D [1,25(OH)2D3], 19-nor-14-epi-23-yne-1,25(OH)2D3 (TX 522) and 19-nor-14,20-bisepi-23-yne-1,25(OH)2D3 (TX 527). Both analogs were more potent (14- and 75-fold, respectively) than 1,25(OH)2D3 in inhibiting cell proliferation and inducing cell differentiation. However, DNA-independent experiments indicated that both analogs had a lower affinity to VDR and that the stability of the induced VDR conformation, as measured by limited protease digestion assays, was similar (TX 527) or even weaker (TX 522) than that induced by the parent compound. However, DNA-dependent assays such as gel shift experiments revealed that those analogs were slightly more potent (3-7 times) than 1,25(OH)2D3 in enhancing binding of VDR-RXR heterodimers to a direct repeat spaced by three nucleotides (DR3) type VDRE. The functional consequences of the ligand-VDR-RXR-VDRE interactions observed in vitro were subsequently evaluated in transfection experiments. Both 14-epianalogs enhanced transcription of VDRE containing reporter constructs more efficiently than 1,25(OH)2D3 in COS-1 and MCF-7 cells regardless of the presence of ketoconazole. Transactivation activity is suggested to be a cell-specific process because maximal transcriptional induction and the half-maximal transactivation concentration for each reporter construct were different in both cell lines. The superagonistic transactivation activity closely resembled the biological potency of these analogs on the inhibition of MCF-7 cell proliferation. These data clearly indicate that superagonistic activity starts beyond the binding of the ligand-heterodimer (VDR-RXR) complex to VDRE and thus probably involves coactivator/corepressor molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315990     DOI: 10.1359/jbmr.2001.16.4.625

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

1.  Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells.

Authors:  Ryoko Okamoto; Remi Delansorne; Naoki Wakimoto; Ngan B Doan; Tadayuki Akagi; Michelle Shen; Quoc H Ho; Jonathan W Said; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2011-08-27       Impact factor: 7.396

2.  Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system.

Authors:  Yingyu Ma; Wei-Dong Yu; Alejandro A Hidalgo; Wei Luo; Remi Delansorne; Candace S Johnson; Donald L Trump
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

Review 3.  Vitamin D metabolism, mechanism of action, and clinical applications.

Authors:  Daniel D Bikle
Journal:  Chem Biol       Date:  2014-02-13

4.  Vitamin D receptor genotypes and kidney allograft rejection.

Authors:  Negar Azarpira; Mohamad M Sagheb; Bita Geramizadeh; Masumeh Darai
Journal:  Mol Biol Rep       Date:  2009-03-19       Impact factor: 2.316

Review 5.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.